The University of Southampton
University of Southampton Institutional Repository

Anaphylaxis as an adverse event following immunisation in the UK and Ireland

Anaphylaxis as an adverse event following immunisation in the UK and Ireland
Anaphylaxis as an adverse event following immunisation in the UK and Ireland
Anaphylaxis is a rare adverse event following immunisation (AEFI) and unlikely to be detected in prelicensure vaccine trials. Previous retrospective studies have been hampered by the paucity of information available to passive reporting schemes. The aim of the present study was to estimate the incidence and clinical presentation of anaphylaxis as an AEFI using prospective active surveillance.

Methods Children under 16 in the UK and Ireland with suspected anaphylaxis as an AEFI were reported through the British Paediatric Surveillance Unit (BPSU) between September 2008 and October 2009. Paediatricians completed questionnaires on presentation, diagnosis, management and outcome.

Results A total of 7 out of 15 reports met criteria for anaphylaxis following immunisation. Four of the seven children reacted more than 30 min after administration of the vaccine. Six children required treatment with intramuscular adrenaline and intravenous fluids, but all made a full recovery. Denominators were not available for all vaccines so an overall incidence was not calculated, however the estimated incidence was 12.0 per 100 000 dose for single component measles vaccine and 1.4 cases per million doses for the bivalent human papilloma virus vaccine (Cervarix, GSK).

Conclusions Anaphylaxis remains a rare adverse event following immunisation. No cases were related to vaccines given as part of the ‘routine’ infant and preschool immunisation programme, despite over 5.5 million vaccines being delivered in this time period. Some children had delayed onset of symptoms and this should be considered when vaccinating those at higher risk of anaphylaxis.
0003-9888
Erlewyn-Lajeunesse, Michel
e1763b6d-165b-45c5-9108-5dc8722220b9
Hunt, Linda P
79158781-3328-4cad-9736-315b9c4cb739
Heath, Paul T
fce44186-c98d-4bdf-8d60-d0f89fff2ce9
Finn, Adam
59ac74fa-55a6-448d-9e19-9dd2f4654d4b
Erlewyn-Lajeunesse, Michel
e1763b6d-165b-45c5-9108-5dc8722220b9
Hunt, Linda P
79158781-3328-4cad-9736-315b9c4cb739
Heath, Paul T
fce44186-c98d-4bdf-8d60-d0f89fff2ce9
Finn, Adam
59ac74fa-55a6-448d-9e19-9dd2f4654d4b

Erlewyn-Lajeunesse, Michel, Hunt, Linda P, Heath, Paul T and Finn, Adam (2012) Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Archives of Disease in Childhood. (doi:10.1136/archdischild-2011-301163).

Record type: Article

Abstract

Anaphylaxis is a rare adverse event following immunisation (AEFI) and unlikely to be detected in prelicensure vaccine trials. Previous retrospective studies have been hampered by the paucity of information available to passive reporting schemes. The aim of the present study was to estimate the incidence and clinical presentation of anaphylaxis as an AEFI using prospective active surveillance.

Methods Children under 16 in the UK and Ireland with suspected anaphylaxis as an AEFI were reported through the British Paediatric Surveillance Unit (BPSU) between September 2008 and October 2009. Paediatricians completed questionnaires on presentation, diagnosis, management and outcome.

Results A total of 7 out of 15 reports met criteria for anaphylaxis following immunisation. Four of the seven children reacted more than 30 min after administration of the vaccine. Six children required treatment with intramuscular adrenaline and intravenous fluids, but all made a full recovery. Denominators were not available for all vaccines so an overall incidence was not calculated, however the estimated incidence was 12.0 per 100 000 dose for single component measles vaccine and 1.4 cases per million doses for the bivalent human papilloma virus vaccine (Cervarix, GSK).

Conclusions Anaphylaxis remains a rare adverse event following immunisation. No cases were related to vaccines given as part of the ‘routine’ infant and preschool immunisation programme, despite over 5.5 million vaccines being delivered in this time period. Some children had delayed onset of symptoms and this should be considered when vaccinating those at higher risk of anaphylaxis.

This record has no associated files available for download.

More information

Published date: 23 January 2012

Identifiers

Local EPrints ID: 508114
URI: http://eprints.soton.ac.uk/id/eprint/508114
ISSN: 0003-9888
PURE UUID: ae8e3703-b10b-41dc-a994-bf9a94011e51
ORCID for Michel Erlewyn-Lajeunesse: ORCID iD orcid.org/0000-0003-1982-1397

Catalogue record

Date deposited: 13 Jan 2026 17:56
Last modified: 17 Jan 2026 03:14

Export record

Altmetrics

Contributors

Author: Michel Erlewyn-Lajeunesse ORCID iD
Author: Linda P Hunt
Author: Paul T Heath
Author: Adam Finn

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×